Jefferies analyst Michael Yee upgraded Amarin to Buy from Hold with a price target of $3, up from $1.30.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMRN:
- Amarin in patent infringement settlement with Health Net, no terms
- Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
- Amarin announces VAZKEPA receives regulatory approval in Switzerland
- Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
- HLS Therapeutics highlights data on RESPECT-EPA study